Smartleaf Asset Management
STOK icon

Smartleaf Asset Management’s Stoke Therapeutics STOK Stock Holding History

Smartleaf Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-155
Closed -$5.02K – 3803
2026
Q2 		$5.02K Hold
155
– – ﹤0.01% 2680
2026
Q1 		$4.92K Hold
155
– – ﹤0.01% 2664
2025
Q4 		$4.93K Buy
+155
New +$4.66K ﹤0.01% 2699

Other funds holding STOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Smartleaf Asset Management's STOK Position: Q3 2026 in Review

Smartleaf Asset Management sold out of Stoke Therapeutics (STOK) in Q3 2026, closing a stake of 155 shares — an estimated $5.02K sold.

Smartleaf Asset Management first reported a position in STOK in Q4 2025 and held it in 3 quarters. The position peaked at $5.02K in Q2 2026. 74 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • Smartleaf Asset Management reported no remaining Stoke Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Smartleaf Asset Management sold 155 Stoke Therapeutics shares in Q3 2026, an estimated $5.02K.
  • Smartleaf Asset Management first reported a position in Stoke Therapeutics in Q4 2025 and held it in 3 quarters.
  • Smartleaf Asset Management's Stoke Therapeutics position peaked at $5.02K in Q2 2026.
  • 74 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.